Autopsy report · NCT03580694

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

“Program reprioritization”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 5 months before it stopped.
• 17 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Regeneron Pharmaceuticals

Sponsor type

Industry

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

REGN4659; Cemiplimab

Participants

17

Sites

6

Countries

United States

Trials that died the same way

• A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
  “Not moving forward with program.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.